The recent
trading activities of
Elevance Health (ticker: ELV), a prominent healthcare firm, have indicated significant shifts. Although several institutional investors, including
Kestra Private Wealth Services LLC and
Chevy Chase Trust Holdings LLC, have diminished their shares in the company, others such as
Banque Pictet & Cie SA and
Asset Management One Co. Ltd. have been purchasing more. Elevance had a tough
Q4 where its share price slipped, although it still managed to announce a
quarterly profit amid investor anxieties. Over the past five years, investment in the company would've yielded a
42% gain. Considering the current market conditions, the company was rated a
Moderate Buy by majority brokerages suggesting potential
growth despite the recent drops. Elevance's potential remains strong, with Q4 sales aligning with estimates and sizeable acquisitions of company shares hinting at investor confidence. However, they faced hurdles with high medical expenses causing a reduction in profit forecasts. Despite this, the company's dividend payout seems promising, having increased compared to the previous year.
Elevance Health ELV News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Sat, 15 Feb 2025 20:05:45 GMT -
Rating 6
- Innovation 7
- Information 7
- Rumor -4
